Skip to main content

ADVERTISEMENT

patient-centered care

Research in Review
09/09/2016
JCP Editors
Vinblastine monotherapy has similar outcomes and a more favorable toxicity profile compared with current therapies when used in patients with treatment naïve pediatric low-grade glioma (PLGG), according to a study...
Vinblastine monotherapy has similar outcomes and a more favorable toxicity profile compared with current therapies when used in patients with treatment naïve pediatric low-grade glioma (PLGG), according to a study...
...
09/09/2016
Journal of Clinical Pathways
Quiz
09/08/2016
JCP Editors
In a Viewpoint found in the most recent issue of Journal of Clinical Pathways, Dr Stephen McKenna contends that oncology patient-reported outcome measures (PROMs) are restrictive because they focus too much on a...
In a Viewpoint found in the most recent issue of Journal of Clinical Pathways, Dr Stephen McKenna contends that oncology patient-reported outcome measures (PROMs) are restrictive because they focus too much on a...
In a...
09/08/2016
Journal of Clinical Pathways
Counterpoint
09/06/2016
Bruce Feinberg, DO
Julia Braverman, PhD
Jennifer Fillman, MBA
Patient-reported outcome (PRO) research has shown that PROs must play a role in the future of health care delivery as the system transitions from volume-based care to value-based care. Building trust among...
Patient-reported outcome (PRO) research has shown that PROs must play a role in the future of health care delivery as the system transitions from volume-based care to value-based care. Building trust among...
...
09/06/2016
Journal of Clinical Pathways
Viewpoint
09/06/2016
Stephen P McKenna, PhD, AFBPsS, CPsychol
Generic patient-reported outcome measures (PROMs) for cancer have outlived their utility. More relevant and accurate PROMs are required in order to demonstrate the true value of oncology interventions to...
Generic patient-reported outcome measures (PROMs) for cancer have outlived their utility. More relevant and accurate PROMs are required in order to demonstrate the true value of oncology interventions to...
...
09/06/2016
Journal of Clinical Pathways
Counterpoint
12/14/2015
Joan S. McClure, MS
Al B. Benson III, MD, FACP, FASCO
Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Cancer care is expensive, and evaluating costs in cancer care is complex. Drug costs are only part...
Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Cancer care is expensive, and evaluating costs in cancer care is complex. Drug costs are only part...
Before...
12/14/2015
Journal of Clinical Pathways